Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB) Short Interest Up 188.7% in February

Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB) was the target of a large growth in short interest in February. As of February 13th, there was short interest totaling 146,372 shares, a growth of 188.7% from the January 29th total of 50,692 shares. Currently, 1.9% of the shares of the stock are sold short. Based on an average daily volume of 124,954 shares, the days-to-cover ratio is currently 1.2 days. Based on an average daily volume of 124,954 shares, the days-to-cover ratio is currently 1.2 days. Currently, 1.9% of the shares of the stock are sold short.

Anebulo Pharmaceuticals Stock Up 0.7%

NASDAQ:ANEB opened at $0.43 on Friday. The firm has a market cap of $17.58 million, a PE ratio of -2.27 and a beta of -0.81. Anebulo Pharmaceuticals has a 12 month low of $0.41 and a 12 month high of $3.42. The company’s 50-day moving average price is $0.92 and its two-hundred day moving average price is $1.91.

Anebulo Pharmaceuticals (NASDAQ:ANEB) last posted its earnings results on Friday, February 13th. The company reported ($0.05) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.13) by $0.08. On average, research analysts expect that Anebulo Pharmaceuticals will post -0.52 EPS for the current fiscal year.

Institutional Trading of Anebulo Pharmaceuticals

A hedge fund recently bought a new stake in Anebulo Pharmaceuticals stock. Goldman Sachs Group Inc. bought a new stake in Anebulo Pharmaceuticals, Inc. (NASDAQ:ANEB) in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 47,954 shares of the company’s stock, valued at approximately $62,000. Goldman Sachs Group Inc. owned approximately 0.12% of Anebulo Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors and hedge funds own 28.40% of the company’s stock.

About Anebulo Pharmaceuticals

Anebulo Pharmaceuticals, Inc (NASDAQ:ANEB) is a clinical‐stage biopharmaceutical company focused on the development of intranasal therapies for the acute treatment of migraine. Its lead product candidate, ANEB-001, is an intranasal formulation of dihydroergotamine mesylate designed to provide rapid relief from migraine attacks while reducing common gastrointestinal side effects associated with oral treatments.

The company is advancing ANEB-001 through pivotal trials in the United States and plans to submit a new drug application to the U.S.